Bellicum Pharmaceuticals Inc
44 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
|Company Name:||Bellicum Pharmaceuticals Inc|
|Stock Symbol :||NASDAQ: BLCM|
|Class Period Start:||05/08/2017|
|Class Period End:||01/30/2018|
|Lead Plaintiff motion:||04/09/2018|
|Type of Case:||Securities Class Action|
|Court:||U.S. District Court for the Southern District of Texas|
Thieler Law Corp advises investors with losses exceeding $100,000 of the April 9, 2018 lead plaintiff deadline in a class action lawsuit filed against Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) (“Bellicum” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of Texas and investors, who purchased Bellicum Pharmaceuticals Inc securities between May 8, 2017, and January 30, 2018, have until April 9, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.
If you purchased Bellicum Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing firstname.lastname@example.org . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.
The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that a substantial undisclosed risk of encephalopathy was associated with the Company’s lead product candidate BPX-501; and as a result of the foregoing, Bellicum’s public statements were materially false and misleading at all relevant times.
On January 30, 2018, the Company issued a press release entitled “Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States,” revealing that it had “received notice from the U.S. Food and Drug Administration that U.S. studies of BPX-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to BPX-501.”
Following this news, NASDAQ: BLCM fell $2.12, or 25.85%, to close at $6.08 on January 31, 2018.
If you were negatively impacted by your investment in Bellicum Pharmaceuticals Inc securities between May 8, 2017, and January 30, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
telephone at +1 (619) 377 - 4324
visit our website http://www.thielerlaw.com/
Facsimile: +1 (619) 785 – 3185